TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GG00B1ZBD492 Issuer Name NB PRIVATE EQUITY PARTNERS LIMITED UK or Non-UK Issuer Non-UK 2. Reason for Notification An acquisition or disposal of voting rights; An event changing the breakdown of voting rights 3. Details of person subject to the notification obligation Name Quilter Plc City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name ...

Core Viewpoint - Autonomix Medical, Inc. is participating in the Virtual Investor Closing Bell Series to showcase its innovative medical device technology focused on precision nerve-targeted treatments [2][3]. Company Overview - Autonomix Medical, Inc. is a medical device company dedicated to advancing technologies for diagnosing and treating diseases related to the nervous system [5]. - The company's first-in-class platform system technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5][6]. Technology and Applications - The initial development of the technology is aimed at treating pain, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [6]. - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [6]. Event Details - The event will feature a corporate overview by Brad Hauser, President and CEO, and will include a live Q&A session for investors and interested parties [3][4]. - The live video webcast will be accessible on the company's website, with a replay available for 90 days following the event [4].

Core Points - Volatus Aerospace Inc. has completed a shares-for-debt transaction, issuing 20,174,280 common shares and 17,640,000 warrants to settle a debt of $3,026,142 [1][2] - The common shares were issued at a deemed price of $0.15 per share, while each warrant is exercisable at $0.20 per share for three years, with potential acceleration based on trading price conditions [2][3] - The transaction is subject to a hold period of four months and one day and requires final approval from the TSX Venture Exchange (TSXV) [3][4] Company Overview - Volatus Aerospace is a leader in global aerial solutions, focusing on intelligence and cargo services, with over 100 years of combined institutional knowledge in aviation [5] - The company serves various industries, including oil and gas, utilities, healthcare, and public safety, aiming to enhance operational efficiency, safety, and sustainability [5]

Core Insights - Silynxcom Ltd. reported a record revenue of $9.1 million for the year ended December 31, 2024, reflecting an 18% increase from the previous year, driven by ongoing expansion and product adoption [6] - The company has introduced innovative products, including an armored personnel carrier headset that enhances battlefield awareness by detecting drone noise while maintaining hearing protection [6] - Silynxcom has received $10 million in orders from the Israel Defense Forces since October 7, 2023, indicating strong demand for its products [6] Financial Highlights - Revenues for 2024 reached $9.1 million, up approximately 18% from the previous year [6] - Gross profit for the year was approximately $3.8 million, a 17% increase compared to $3.2 million in the previous year [6] - Cash and cash equivalents as of December 31, 2024, totaled $3.2 million [6] Corporate Developments - The company closed an underwritten public offering on April 2, 2025, generating gross proceeds of approximately $2.9 million [6] - Silynxcom expanded its sales operations in the Asia Pacific region, enhancing its market presence [6] - The company successfully completed field trials for its innovative in-ear communication solution aimed at boosting situational awareness and safety for military personnel [6]

Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) and snoring in adults, as well as moderate to severe OSA in children aged 6 to 17 [4] - The company's devices have received FDA clearance for treating all severity levels of OSA in adults and moderate to severe OSA in children [4] - Vivos' CARE devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children [4] Industry Context - OSA affects over 1 billion people globally, with 90% remaining undiagnosed [5] - The disorder is linked to various serious chronic health conditions, indicating a significant unmet need in the market for effective treatment solutions [5] - Current solutions often fail to address the root causes of OSA, highlighting the importance of innovative approaches like those offered by Vivos [5] Upcoming Events - Vivos plans to release its first quarter 2025 financial results after market close on May 15, 2025, followed by a conference call at 5:00 p.m. ET to discuss the results and recent developments [1] - The conference call can be accessed via a dedicated phone line and will also be available as a live webcast on the company's website [2][3] Innovative Approach - The Vivos Method provides a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, aiming to improve patient outcomes in sleep health [7] - The company collaborates with healthcare providers, including dentists and sleep specialists, to address the complex needs of patients suffering from sleep-related disorders [6]

Core Insights - Renovaro Inc. has launched Augusta, a Precision Neurology Platform aimed at improving patient stratification, biomarker discovery, and drug validation in neurology, an area that has historically faced challenges in diagnosis and treatment [1][2] Group 1: Platform Features - Augusta integrates multimodal data analytics with proprietary in silico screening, significantly reducing the time required for identifying biomarkers and therapeutics compared to conventional methods [1] - The platform emphasizes interpretability, clinical alignment, and rigorous benchmarking, moving away from black-box approaches [2] - Its modular infrastructure allows for plug-and-play model evaluation, including large language models conditioned with proprietary knowledge graphs, fostering continuous innovation while ensuring clinical robustness [2] Group 2: Validation and Efficacy - The efficacy of Augusta has been demonstrated in Parkinson's Disease through phenoclustering, which identified novel patient subgroups with unique clinical characteristics and biomarkers [3] - In epilepsy, the platform has successfully identified novel lead compounds targeting patient populations with rare genetic mutations [3] Group 3: Future Plans - Renovaro plans to expand its precision neurology efforts into additional neurological disorders and is currently discussing strategic partnerships with academic medical centers and life sciences companies [4] Group 4: Company Overview - Renovaro aims to accelerate precision and personalized medicine for longevity by leveraging AI and biotechnology platforms for early diagnosis, targeted treatments, and drug discovery [5]

Core Insights - SEALSQ Corp plans to invest $10 million in WISeSat.Space to enhance satellite constellation deployment and secure communications through Quantum Key Distribution (QKD) technology [1][2] - This investment aims to establish a quantum-resilient satellite network for ultra-secure communications and transactional IoT services [2] - The global quantum communication market is projected to grow at a CAGR of 31.8% from 2025 to 2030, reaching over $1 billion in 2024, driven by the need for enhanced security across various sectors [5] Investment and Strategic Goals - SEALSQ's investment is subject to final approval by its Board of Directors and represents a significant step towards building a secure satellite network [2] - The investment will enable SEALSQ to connect and secure trillions of IoT devices globally, creating a "Satellite-as-a-Service" revenue model [4] - The upcoming June 2025 mission will demonstrate SEALCOIN's capability for decentralized transactions between satellites and IoT devices [3] Technology and Market Position - QKD provides unmatched security by utilizing quantum mechanics, making it essential for safeguarding sensitive data in finance, healthcare, and defense [6][8] - SEALSQ and WISeKey aim to capture a leadership position in the quantum communication market by integrating QKD with satellite infrastructure [6] - The deployment of WISeKey's Quantum RootKey will ensure secure transactions and data privacy, protecting against both classical and quantum threats [10] Future Developments - WISeKey is preparing for multiple satellite deployments in 2025 to expand its network and enhance IoT connectivity [7] - The industrialization of WISeSat's Satellite-as-a-Service platform is expected to accelerate the adoption of quantum-secure services globally [11] - SEALSQ's focus on Post-Quantum Technology aims to address security challenges posed by advancing quantum computing [12][13]

Core Insights - AgEagle Aerial Systems Inc. has sold 20 RedEdge-P cameras to Wingtra, enhancing their partnership and capabilities in precision agriculture and geospatial applications [1][2][3] Company Overview - AgEagle Aerial Systems Inc. is a leading provider of drone and aerial imaging solutions, focusing on advanced technology for various industries including agriculture, construction, and energy [5] - The company was founded in 2010 and has developed a reputation for professional-grade fixed-wing drones and aerial data collection solutions [5] Product Details - The RedEdge-P camera is designed for professional drone operations, offering survey-grade accuracy with resolutions down to 2cm [3] - The camera utilizes advanced optics and industrial image sensors, making it suitable for applications in agriculture, environmental monitoring, and water management [2][3][4] Partnership Impact - The collaboration between AgEagle and Wingtra aims to deliver high-quality aerial mapping and surveying solutions, expanding the use of Wingtra drones across various industries [2][4] - This transaction is seen as a reinforcement of AgEagle's commitment to providing reliable imaging solutions that drive efficiency and innovation for end users [3]

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced the appointment of Morehouse School of Medicine’s Regional Dean for Seattle and Puget Sound’s Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (M ...

Please find enclosed the presentation of the preliminary first quarter results to be held May 14, 2025, in the link below. Attachment SFL - First Quarter 2025 Results Presentation ...